When existing models are insufficient to address your therapy’s unique mechanisms, BioLegacy provides bespoke model development services to create the precise in vivo system your program requires. Our multidisciplinary team of scientists and veterinary surgeons collaborates with you to design, engineer, and validate novel models that accurately recapitulate the relevant aspects of human disease pathology. With deep expertise across a comprehensive range of species — from genetically engineered rodents to surgically modified large animals, including non-human primates — we deliver highly translatable, purpose-built models that provide definitive answers to your most critical preclinical challenges.
The most faithful recapitulation of human disease states with genetic bases often requires reproducing mutations in model species. BioLegacy provides a comprehensive service for the development and deployment of genetically engineered models. We create the precise knockout, knock-in, or transgenic models needed for definitive target validation, mechanism-of-action, and efficacy studies, providing a direct and unambiguous link between genetic modulation and phenotypic outcome.
To accurately evaluate therapeutics for conditions rooted in anatomical or injury-based pathology, a model must be created with surgical precision. Our highly skilled veterinary surgeons specialize in this, operating in state-of-the-art surgical suites to create consistent and reproducible models of complex diseases. Led by renowned veterinary surgeon Dr. DingGang Liu, an expert in microsurgeries, we have the ability to perform exactingly precise surgeries to induce the necessary pathologies for your study, providing the ideal platform to generate pivotal efficacy and safety data.
The pathological state of many systemic diseases are best replicated by introducing toxins, nutrients, or otherwise altering the homeostasis of an organism. We leverage a deep knowledge of pharmacology and physiology to implement a wide array of chemically-induced and diet-induced models. Modifications to the induction protocol enable precise calibration of disease severity and provide a robust, clinically relevant system for evaluating the efficacy of novel therapeutics.
Any novel in vivo model is incomplete without a rigorous validation process to ensure it is fit-for-purpose. Every custom model developed at BioLegacy undergoes a comprehensive characterization to confirm it faithfully recapitulates the key aspects of the human condition. Our multi-modal approach integrates functional, biomarker, and histological data to provide you with complete confidence in the model’s translational relevance and the integrity of your study results.
We’ve been advancing therapeutic programs for 25 years.